EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: A systematic review and meta-analysis

Radiotherapy and Oncology

Volumn 114, Issue 2, 2015, Pages 167-172

  Soon, Yu Yang ^a   Leong, Cheng Nang ^a   Koh, Wee Yao ^a   Tham, Ivan Weng Keong ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Epidermal growth factor receptor tyrosine; kinase inhibitors; Non small cell lung cancer; Stereotactic radiation therapy; Whole brain radiation therapy

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MUTANT PROTEIN; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

BRAIN METASTASIS; BRAIN RADIATION; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; GENE MUTATION; HUMAN; LARGE CELL LUNG CARCINOMA; META ANALYSIS; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION RESPONSE; REVIEW; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROCEDURES; SECONDARY; SKULL IRRADIATION;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84926168201     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.12.011     Document Type: Article

References (40)

1. J.S. Barnholtz-Sloan, A.E. Sloan, and F.G. Davis Incidence proportions of brain metastases in patients diagnosed 91973-2001) in the Metropolitan Detroit Cancer Survelliance System J Clin Oncol 22 2004 2865 2872
2. H.J. Mamon, B.Y. Yeap, and P.A. Janne High risk of brain metastases in surgically staged IIIA non-small cell lung cancer patients treated with surgery, chemotherapy, and radiation J Clin Oncol 23 2005 1530 1537
3. A. Sekine, T. Kato, and E. Hagiwara Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features Lung Cancer 77 2012 64 69
4. D.Y. Shin, I.I. Na, C.H. Kim, S.H. Park, H.J. Baek, and S.H. Yang EGFR mutation and brain metastasis in pulmonary adenocarcinomas J Thorac Oncol 9 2014 195 199
5. L. Daniele, P. Cassoni, and E. Bacillo Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer J Thorac Oncol 6 2009 684 688
6. M. Sun, C. Behrens, and L. Feng HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors Clin Cancer Res 15 2009 4829 4837
7. P. Sperduto, N. Kased, and D. Roberge Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases J Clin Oncol 30 2012 419 425
8. M. Tsao, D. Rades, and A. Wirth Radiotherapuetic and surgical management for newly diagnosed brain metastasis (es): An American Society for Radiation Oncology evidence-based guideline Pract Radiat Oncol 2 2012 210 225
9. S. Scoccianti, and U. Ricardi Treatment of brain metastases: review of phase III randomized controlled trials Radiother Oncol 102 2012 168 179
10. J. Li, S.M. Bentzen, and M. Renschler Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function J Clin Oncol 25 2007 1260 1266
11. E.L. Chang, J.S. Wefel, and K.R. Hess Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain irradiation: a randomized controlled trial Lancet Oncol 10 2009 1037 1044
12. M. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K.M. Kerr, and S. Peters Metastatic non-small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up Ann Oncol 2014 Epub ahead of Print
13. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
14. B. Weber, M. Winterdahl, and A. Memon Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harbouring a mutation in the epidermal growth factor receptor J Thorac Oncol 6 2011 1287 1289
15. S.M. Lee, C. Lewanski, and N. Counsell Randomized trial of Erlotinib plus whole brain radiotherapy for NSCLC patients with multiple brain metastases J Natl Cancer Inst 2014 Epub ahead of Print
16. S.J. Park, H.T. Kim, and D.H. Lee Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harbouring either exon 19 or 21 mutation Lung Cancer 77 2012 556 560
17. Y.L. Wu, C. Zhou, and Y. Cheng Erlotinib as second line treatment in patients with advanced non-small cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803) Ann Oncol 24 2013 993 999
18. T. Luchi, M. Shingyoji, and T. Sakaida Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR mutant lung adenocarcinoma Lung Cancer 82 2013 282 287
19. Wells G.A., Shea B., O'Connell D., et al. The Newcastle-Ottawa Scale for assessing the quality of non-randomized studies in meta-analyses. 2014. < http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp > (accessed August 24, 2014).
20. L.D. Brown, T.T. Cat, and A. DasGupta Interval estimation for a proportion Stat Sci 16 2001 101 133
21. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
22. J.P. Higgins, S.G. Thompson, and J.J. Deeks Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
23. D.G. Altman, and J.M. Bland Interaction revisited: the difference between two estimates BMJ 326 2003 219
24. C.H. Gow, C.R. Chien, and Y.L. Chang Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response Clin Cancer Res 14 2008 162 168
25. A.F. Eichler, K.T. Kahle, and D.L. Wang EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer Neuro Oncol 12 2010 1193 1199
26. R. Porta, J.M. Sanchez-Torres, and L. Paz-Ares Brain metastasis from lung cancer responding to erlotinib: the importance of EGFR mutation Eur Respir J 37 2011 624 631
27. Y.D. Zeng, L. Zhang, and H. Lian Gefitnib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small cell lung cancer: a retrospective study Asian Pacific J Cancer Prev 13 2012 909 914
28. H.Q. Zhuang, Z.Y. Yuan, J. Wang, L.J. Zhao, Q.S. Pang, and P. Wang Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma Drug Des Dev Ther 7 2013 1179 1186
29. J.W. Welsh, R. Komaki, and A. Amini Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer J Clin Oncol 31 2013 895 902
30. M. Schuler, J.C.H. Yang, and L.V. Sequist Efficacy of afatinib versus chemotherapy in treatment naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease J Thorac Oncol 8 2013 S299
31. S.H. Hsiao, H.C. Lin, and Y.T. Chou Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients Lung Cancer 81 2013 455 461
32. N.K. Gerber, Y. Yamada, and A. Rimner Erlotinib versus radiation therapy for brain metastases in patients with EGFR mutant lung adenocarcinoma Int J Radiat Oncol Biol Phys 89 2014 322 329
33. M. Jamal-Hanjani, and J. Spicer Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutant non-small cell lung cancer metastatic to the brain Clin Cancer Res 18 2012 938 944
34. M. Bartolotii, E. Franceschi, and A.A. Brandes EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small cell lung cancer Expert Rev Anticancer Ther 11 2012 1429 1435
35. S. Zimmermann, R. Dziadziuszko, and S. Peters Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases Cancer Treat Rev 40 2014 716 722
36. M. Kocher, R. Soffietti, and U. Abacioglu Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study J Clin Oncol 29 2011 134 141
37. F. Burel-Vandenbos, D. Ambrosetti, M. Coutts, and F. Pedeutour EGFR mutation status in brain metastases of non-small cell lung cancer J Neurooncol 111 2013 1 10
38. G. Robinet, P. Thomas, and J.L. Breton Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1 Ann Oncol 12 2001 59 67
39. D.H. Lee, J.Y. Han, and T.H. Kim Primary chemotherapy for newly diagnosed non-small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first Cancer 113 2008 143 149
40. S.H. Lim, J.Y. Lee, and M.Y. Lee Randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small cell lung cancer (NSCLC) J Clin Oncol 32 2014 5s suppl; abstr 8037